Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025
Import Alert Set To Wipe $385m From Adjusted EBITDA; Core Lenalidomide Not Exempt
Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.
